WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.

For more than two decades, the global community has united to fight the HIV pandemic, achieving remarkable progress. New HIV transmissions and AIDS-related deaths have dropped significantly, and ...

Coalition of Women Living with HIV and Aids (Cowlha) says an initiative they introduced to promote adherence to ...

Six months after President Donald Trump's foreign aid cuts, millions have lost access to HIV prevention medication.

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

This isn't about managing the AIDS pandemic. It's about ending it -- and letting a new generation grow and thrive free of its threat.We stand at the edge of an extraordinary possibility: to end the ...

A decade ago, the global community established the goal to end AIDS as a public health threat by 2030 through reducing new HIV infections and AIDS-related deaths by 90% from 2010 levels.1 Progress has ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

Global HIV leaders have urged African countries to fully own their HIV responses and called on governments to urgently invest ...